Ionis reports fourth quarter and full year 2022 financial results
Eplontersen NDA submitted to FDA; tofersen under regulatory review for marketing approval in U.S. and EU Phase 3 data planned for eplontersen and olezarsen; robust late-stage pipeline expanding with two new Phase 3 programs Ionis provides full year 2023 financial guidance CARLSBAD,…
Comments Off on Ionis reports fourth quarter and full year 2022 financial results